Clinical trial data indicate that both sorafenib and sunitinib are able to improve progression-free survival and overall survival in RCC patients by targeting the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) [3, 4]. The gene discussed is KDR; the disease is renal cell carcinoma.